ISRCTN13784998已完成1 期
A Phase 1, partially Blind, Placebo-Controlled, Ascending Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects and Osteoarthritis Patients administered APPA-1
Research Support Office0 个研究点目标入组 28 人开始时间: 2018年1月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Written informed consent
- •2. Between 18 and 75 years of age, inclusive
- •3. Of any ethnic origin
- •4. Healthy male subjects (groups A1 to A4)
- •5. Healthy female subjects (group A5)
- •6. BMI between 18.0 to 35.0 kg/m2
- •7. In good health as defined by medical history (including confirmation from GP), physical examination, vital signs assessment, 12 lead ECG and clinical laboratory evaluation.
- •1. Written informed consent
- •2. Between 18 and 75 years of age inclusive
- •3. Of any ethnic origin
- •4. Male or female subjects with a diagnosis of osteoarthritis fulfilling the American College of Rheumatology (ACR) criteria for diagnosis
- •5. BMI between 18.0 to 35.0 kg/m2
排除标准
- •Part A & B:
- •1. Male subjects who do not agree, or whose partners of childbearing potential do not agree, to use appropriate contraception or to refrain from donating sperm from the time of dosing until the Follow Up Visit.
- •2. Female of childbearing potential not in agreement to use two highly effective methods of contraception, or to refrain from donating ova, from the time of screening until the Follow Up Visit
- •3. Donated blood in the 3 months prior to screening, plasma in the 7 days prior to screening, platelets in the 6 weeks prior to screening
- •4. Consume more than 28 units of alcohol per week if male, or 21 units of alcohol per week if female or any significant history of alcohol / substance misuse as determined by the investigator
- •5. Unwilling to abstain from vigorous exercise for 48 hours prior to any study visit
- •6. Unwilling to abstain from alcohol for 48 hours prior to any study visit
- •7. Received any medication, including St John’s Wort, known to chronically alter drug absorption or elimination within 30 days prior to first dose administration unless in the opinion of the investigator it will not interfere with study procedures or compromise safety
- •8. Subjects who have any abnormality of vital signs prior to the first dose administration that, in the opinion of the investigator, would increase the risk of participating in the study
- •9. Subjects who have any clinically significant abnormal physical examination finding
- •10. Subjects who have any clinically significant 12 lead ECG abnormality that, in the opinion of the investigator, would increase the risk of participating in the study
- •11. Subjects who have any clinically significant allergy or allergic condition as determined by the investigator (with the exception of non-active hay fever)
- •12. Subjects who have any clinically significant abnormal laboratory safety results as determined by the investigator with specific exclusions of any AST or ALT greater than or equal to 1.5 times ULN at screening or day -1; total bilirubin > ULN (Gilbert’s syndrome is acceptable)
- •13. Subjects who have hepatitis B or C or are carriers of HBsAg or are carriers of HCV Ab or are positive for HIV 1/2 antibodies.
- •14. Subjects who have a positive alcohol breath test or a positive urine drug screen ( a repeat assessment is acceptable)
- •15. Subjects who are still participating in another clinical study or who have participated in a clinical study involving administration of an investigational product in the 3 months (or 5 half-lives, whichever is longer) prior to first dose administration
- •16. Subjects who have previously received APPA or its constituent parts within 3 months of receiving first dose.
- •17. Subjects who, in the opinion of the investigator, should not participate in this study.
- •18. Tobacco smoking within last 30 days, including use of e-cigarettes and not willing to abstain from smoking until after study involvement.
- •Part A exclusions only:
- •1. Female subjects who are pregnant or currently lactating
- •2. Received any prescribed systemic or topical medication within 14 days prior to the first dose administration (with the exception of the OCP)
研究者
相似试验
进行中（未招募）
不适用
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with Moderate to Severe COPD - PACEChronic Obstructive Pulmonary DiseaseEUCTR2005-004110-32-DEAstraZeneca AB190
已完成
不适用
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil-G30G30PER-123-09ASTRAZENECA PERU S.A.,
进行中（未招募）
1 期
Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabètes Post Worsening Heart Failure (SOLOIST-WHF Trial)Cardiovascular diseasesMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-003510-16-FRSanofi-aventis Recherche & Développement6,667
进行中（未招募）
1 期
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-002954-35-SKsanofi-aventis recherche & développement5,000
进行中（未招募）
1 期
Efficacy and Safety of Sotagliflozin versus Placebo in Subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control while Taking Insulin Alone or with Other Oral Antidiabetic AgentsType 2 diabetes mellitusMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-001804-43-HUSanofi-aventis Recherche & Développement800